S&P 500 Gains and Losses Today: Eli Lilly Stock Falls as Sales Outlook Weakens
Key Takeaways The S&P 500 added 0.1% on Tuesday, Jan. 14, as tame wholesale inflation data provided a positive signal ahead ...
Eli Lilly & Co. stock underperforms Tuesday when compared to competitors
Shares of Eli Lilly & Co. LLY slipped 6.59% to $744.91 Tuesday, on what proved to be an all-around great trading session for ...
Eli Lilly Stumbled But Weight-Loss Drugs Will Continue to Fuel Markets. Here’s Why and 5 Other Things to Know Today.
SEC sues Elon Musk over Twitter purchase, Microsoft says businesses should get quantum ready in 2025, and more news to start ...
What To Expect From PFE Stock In 2025?
In this note, while we briefly touch upon Pfizer’s performance in 2024, we focus on the impact on PFE stock and how 2025 ...
S&P 500 edges higher, Nasdaq dips in choppy session as inflation data eyed
The S&P 500 edged higher while the Nasdaq dipped after a volatile session on Tuesday as investors gauged inflation data and ...
Microsoft, Applied Digital, Rigetti Computing, Eli Lilly, Tesla: Why These 5 Stocks Are On Investors' Radars Today
The U.S. stock market experienced mixed results on Tuesday. The Dow Jones index climbed over 220 points to 42,518.28, while ...
Morningstar4d
Mounjaro and Zepbound sales disappoint, and Eli Lilly's stock is dropping
are used in diabetes and obesity drugs like Eli Lilly's Mounjaro and Zepbound. The stock (LLY) dropped 8.2% in morning trading, enough to make it the S&P 500 index's SPX worst performer.
Wall Street mostly rises after encouraging inflation data despite Lilly's drag
Stubbornly high readings on inflation and a run of better-than-expected readings on the U.S. economy have sent Wall Street ...